Liposomal Bupivacaine After Cesarean Delivery

• Status: Withdrawn
• Trial end date: 2020-07-31
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to determine if local wound infiltration with liposomal bupivacaine at the time of cesarean delivery can decrease opioid use and provide adequate post-operative pain control.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wright State University
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• Are between 18 and 45 years of age, inclusive.

• Are undergoing a planned, primary or repeat, cesarean delivery without permanent sterilization.

• Have a BMI ≤ 60.

• Are able to read and understand English.

Exclusion Criteria:

• Have pre-eclampsia with severe features.

• Has been taking medication assisted treatment for opioid addiction during this pregnancy.

• Have known sensitivity to local anesthetic.

• Have a known sensitivity to non-steroidal anti-inflammatory medications.

• Planning to have a tubal ligation after the cesarean delivery.

• Are unable to receive neuraxial analgesia and/or Duramorph, a morphine formulation that is the standard of care for intrathecal anesthesia at MVH.

• Are prisoners.